Shopping Cart
- Remove All
Your shopping cart is currently empty
Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 50 mg | $51 | In Stock | |
| 100 mg | $77 | In Stock | |
| 500 mg | $223 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $54 | In Stock |
| Description | Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials. |
| Targets&IC50 | HMG-CoA reductase:1 nM(ki) |
| In vitro | Mevastatin competitively inhibits HMG-CoA reductase, subsequently reducing cholesterol synthesis in the liver. After 14 days of high-dose treatment, a more than 30% increase in baseline absolute cerebral blood flow was observed. Oral administration of Mevastatin at doses of 5 mg/kg and 20 mg/kg led to reductions in serum cholesterol levels 3 hours post-administration, with the 20 mg/kg dosage decreasing serum cholesterol by approximately 30%. |
| In vivo | The bicyclic portion of Mevastatin binds to the active site of coenzyme A. Mevastatin elevates eNOS mRNA and protein levels, reduces infarct size, and ameliorates neurological deficits in a dose- and time-dependent manner. At a concentration of 0.01 pg/mL (26 nM), Mevastatin can reduce cholesterol synthesis by 50% compared with the control group. |
| Synonyms | ML236B, Compactin |
| Molecular Weight | 390.51 |
| Formula | C23H34O5 |
| Cas No. | 73573-88-3 |
| Smiles | C(C[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]2[C@]3([C@@H](OC([C@H](CC)C)=O)CCC=C3C=C[C@@H]2C)[H] |
| Relative Density. | 1.13 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (128.04 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) H2O: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.12 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.